<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04034485</url>
  </required_header>
  <id_info>
    <org_study_id>LIB003-003</org_study_id>
    <nct_id>NCT04034485</nct_id>
  </id_info>
  <brief_title>Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH</brief_title>
  <official_title>Randomized, Open-Label, Cross-Over, Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in Homozygous Familial Hypercholesterolemia Patients on Stable Lipid-Lowering Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LIB Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LIB Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the safety, tolerability and LDL-C response after 24 Weeks of monthly (every 4
      weeks [Q4W]) subcutaneous (SC) dosing of LIB003 300 mg with monthly (Q4W) SC dosing of 420 mg
      evolocumab (Repatha®) in patients with HoFH on stable diet and oral LDL-C-lowering drug
      therapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with verified HoFH on stable and continuing doses of oral lipid lowering therapy
      will be randomized to either evolocumab 420 mg Q4W or LIB003 300 mg Q4W for 24 weeks (Period
      A). At Week 24, subjects will be crossed over to LIB003 if they were on evolocumab and vice
      versa for the next 24 weeks (Period B).
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">November 7, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>open label, randomized, cross-over</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>treatment is open label but lipid results are masked to participant and investigator</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percent reduction in Low Density Lipoprotein Cholesterol (LDL-C) at week 24</measure>
    <time_frame>baseline to 24 weeks on each treatment</time_frame>
    <description>Change in serum LDL-C from baseline after 24 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence and severity of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>baseline to 24 weeks on each treatment</time_frame>
    <description>safety and tolerability will be based on the incidence and severity of treatment emergent adverse events</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percent reduction in lipoprotein (a) [Lp(a)] at week 24</measure>
    <time_frame>baseline to 24 weeks on each treatment</time_frame>
    <description>Change in serum Lp(a) from baseline after 24 weeks</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent reduction in apolipoprotein B (Apo B) at week 24</measure>
    <time_frame>baseline to 24 weeks on each treatment</time_frame>
    <description>Change in serum Apo B from baseline after 24 weeks</description>
  </other_outcome>
  <other_outcome>
    <measure>Presence of anti LIB003 antibodies (ADAs)</measure>
    <time_frame>baseline to 24 weeks</time_frame>
    <description>Measurement of ADAs at baseline and various intervals</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Homozygous Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>LIB003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg SC Q4W</description>
  </arm_group>
  <arm_group>
    <arm_group_label>evolocumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>420 mg SC Q4W</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LIB003</intervention_name>
    <description>PCSK9 inhibitor</description>
    <arm_group_label>LIB003</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>evolocumab</intervention_name>
    <description>PCSK9 inhibitor</description>
    <arm_group_label>evolocumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HoFH diagnosed either clinically or genetically

          -  Weight of &gt;30 kg and body mass index (BMI) &gt;18 and &lt;40 kg/m2

          -  stable diet and lipid-lowering oral therapies for at least 4 weeks

        Exclusion Criteria:

          -  mipomersen within 6 months of screening;

          -  LDL or plasma apheresis &lt;2 months prior to randomization

          -  history of non-response to PCSK9 mAb or presence of receptor negative/null LDLR
             activity expected to result in non-response to PCSK9 inhibition

          -  prior or active clinical condition or acute and/or unstable systemic disease
             compromising subject inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evan A Stein, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>LIB Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NorthShore University Health System</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metabolic &amp; Atherosclerosis Research Center (MARC)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medicine, Hadassah University Hospital</name>
      <address>
        <city>Jerusalem</city>
        <zip>12000</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center, Beilinson Hospital,</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lipid Clinic, Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0586</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carbohydrate and Lipid Metabolism Research Unit</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Lipidology, Department of Medicine University of Cape Town</name>
      <address>
        <city>Cape Town</city>
        <state>Western Province</state>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ege University Medical School</name>
      <address>
        <city>İzmir</city>
        <state>Bornova</state>
        <zip>35040</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>Norway</country>
    <country>South Africa</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 22, 2019</study_first_submitted>
  <study_first_submitted_qc>July 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2019</study_first_posted>
  <last_update_submitted>April 21, 2020</last_update_submitted>
  <last_update_submitted_qc>April 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LDL cholesterol</keyword>
  <keyword>PCSK9 inhibition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Evolocumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

